- Home
- AEVA vs PROK Comparison
AEVA vs PROK Comparison
Compare AEVA & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEVA
- PROK
- Stock Information
- Founded
- AEVA 2019
- PROK 2015
- Country
- AEVA United States
- PROK United States
- Employees
- AEVA N/A
- PROK N/A
- Industry
- AEVA Auto Parts:O.E.M.
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AEVA Consumer Discretionary
- PROK Health Care
- Exchange
- AEVA Nasdaq
- PROK Nasdaq
- Market Cap
- AEVA 241.9M
- PROK 212.4M
- IPO Year
- AEVA N/A
- PROK N/A
- Fundamental
- Price
- AEVA $4.35
- PROK $1.80
- Analyst Decision
- AEVA Buy
- PROK Buy
- Analyst Count
- AEVA 5
- PROK 5
- Target Price
- AEVA $10.53
- PROK $4.50
- AVG Volume (30 Days)
- AEVA 500.9K
- PROK 537.9K
- Earning Date
- AEVA 03-04-2025
- PROK 11-12-2024
- Dividend Yield
- AEVA N/A
- PROK N/A
- EPS Growth
- AEVA N/A
- PROK N/A
- EPS
- AEVA N/A
- PROK N/A
- Revenue
- AEVA $7,980,000.00
- PROK N/A
- Revenue This Year
- AEVA $109.02
- PROK N/A
- Revenue Next Year
- AEVA $63.91
- PROK N/A
- P/E Ratio
- AEVA N/A
- PROK N/A
- Revenue Growth
- AEVA 176.22
- PROK N/A
- 52 Week Low
- AEVA $2.20
- PROK $1.18
- 52 Week High
- AEVA $7.25
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- AEVA 49.42
- PROK 53.24
- Support Level
- AEVA $4.27
- PROK $1.50
- Resistance Level
- AEVA $4.61
- PROK $1.82
- Average True Range (ATR)
- AEVA 0.36
- PROK 0.14
- MACD
- AEVA -0.04
- PROK 0.01
- Stochastic Oscillator
- AEVA 26.19
- PROK 76.14
About AEVA Aeva Technologies Inc.
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.